Correlation between Duffy blood group phenotype and breast cancer incidence

BMC Cancer

Xiao-feng Liu¹  Lian-fang Li²  Zhou-luo Ou¹  Rong Shen³  Zhi-min Shao¹ 

[1] Department of Breast surgery, Cancer Hospital/Cancer Institute, Department of Oncology, Fudan University, Shanghai, 200032, People's Republic of China

[2] Department of Breast, Henan Province Tumor Hospital, Zhengzhou, 450008, People's Republic of China

[3] Department of gynaecology/obstetrics, Nanjing Maternity and Child Health Hospital of Nanjing Medical University, Nanjing, 210004, People's Republic of China

关键词: Breast cancer;    Duffy antigen/receptor for chemokines (DARC);    Duffy blood group;   

Others  :  1080234
DOI  :  10.1186/1471-2407-12-374

 received in 2012-01-27, accepted in 2012-08-20,  发布年份 2012

【 摘 要 】

Background

Different ethnicities have different distribution of Duffy blood group (DBG) phenotypes and different breast cancer morbidity. A study in our lab demonstrated that Duffy antigen/receptor for chemokines (DARC, also known as DBGP, the Duffy protein phenotype), led to the inhibition of tumorigenesis. Therefore, we tested the hypothesis that DBGP is correlated with breast cancer occurrence.

Methods

DBGP proteins were examined by indirect antiglobulin testing with anti-FYa and anti-FYb antibodies. The phenotypes were classified into four groups according to the agglutination reactions: FYa + FYb+, FYa + FYb-, FYa-FYb + and FYa-FYb-. The phenotypes and pathological diagnosis of consecutively hospitalized female patients (n = 5,022) suffering from breast cancer at the Shanghai Cancer Hospital and Henan Province Cancer Hospital were investigated. The relationships between DBGP expression with breast cancer occurrence, axillary lymph status, histological subtype, tumor size pathological grade and overall survival were analyzed.

Results

The incidence of breast cancer was significantly different between FYa + FYb + (29.8%), FYa + FYb- (33.2%), FYa-FYb + (45.6%) and FYa-FYb- (59.1%; P = 0.001). Significant different numbers of breast cancer patients had metastases to the axillary lymph nodes in the FYa + FYb + group (25.1%), FYa + FYb- (36.9%), FYa-FYb + (41.0%) and FYa-FYb- (50.0%, (P = 0.005). There was a statistical significance (p = 0.022) of the overall survival difference between patients with difference phenotypes. No significant difference was observed in cancer size (t-test, p > 0.05), histological cancer type (Fisher's exact test, p > 0.05) or histological grade (Fisher's exact test, p > 0.05) between every each DBGP group.

Conclusions

DBGP is correlated with breast cancer incidence and axillary lymph node metastasis and overall survival. Further investigations are required to determine the underlying mechanism of Duffy blood group phenotype on breast cancer risk.

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Pogo AO, Chaudhuri A: The Duffy protein: a malarial and chemokine receptor. Semin Hematol 2000, 37:122-129.
• [2]Akalin E, Neylan JF: The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation 2003, 75:1496-1500.
• [3]Neote K, Mak JY, Kolakowski LF Jr, Schall TJ: Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 1994, 84:44-52.
• [4]Chaudhuri A, Zbrzezna V, Polyakova J, Pogo AO, Hesselgesser J, Horuk R: Expression of the Duffy antigen in K562 cells. Evidence that it is the human erythrocyte chemokine receptor. J Biol Chem 1994, 269:7835-7838.
• [5]Horuk R, Wang ZX, Peiper SC, Hesselgesser J: Identification and characterization of a promiscuous chemokine-binding protein in a human erythroleukemic cell line. J Biol Chem 1994, 269:17730-17733.
• [6]Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, Durda P, Dehghan A, Bis JC, Illig T, Morrison AC, Jenny NS, Keaney JF Jr, Gieger C, Tilley C, Yamamoto JF, Khuseyinova N, Heiss G, Doyle M, Blankenberg S, Herder C, Walston JD, Zhu Y, Vasan RS, Klopp N, Boerwinkle E, Larson MG, Psaty BM, Peters A, Ballantyne CM, Witteman JC, Hoogeveen RC, Benjamin EJ, Koenig W, Tracy RP: Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2010, 115:5289-5299.
• [7]Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY: Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004, 10:7157-7162.
• [8]Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A: Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006, 12:478-486.
• [9]Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001, 7:285-289.
• [10]Addison CL, Belperio JA, Burdick MD, Strieter RM: Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 2004, 4:28. BioMed Central Full Text
• [11]Lentsch AB: The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J 2002, 16:1093-1095.
• [12]Thomas L: Malaria gene linked to prostate-cancer incidence. Lancet Oncol 2005, 6:266.
• [13]Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, Shao ZM: Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 2006, 25:7201-7211.
• [14]Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB: The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 2006, 20:59-64.
• [15]Sucharita B, Rui Z, Asok C, Misako W, Pai SK, Shigeru H, Sadahiro H, Taisei T, Kunio M, Yukio T, Ken S, Pauza ME, Sunao H, Ying W, Sonia M, Tomoyuki M, Megumi I, Eiji F, Kounosuke W: Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006, 12:933-938.
• [16]Zijlstra A, Quigley JP: The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel. Canc Cell 2006, 10:177-178.
• [17]Ou ZL, Wang J, Hou YF, Luo JM, Shen ZZ, Shao ZM: Downregulation of Duffy antigen receptor for chemokine (DARC) is associated with lymph node metastasis in human breast cancer. Zhonghua Zhong Liu Za Zhi 2006, 28:586-589.
• [18]Pittoni V, Vaglio S, Magrini L, Accorinti M, Pivetti-Pezzi P, Girelli G, Valesini G: Polymorphism of the Duffy erythrocyte chemokine receptor in Italian patients with Behcet's disease. Rheumatol Int 2003, 23:116-120.
• [19]Tournamille C: Molecular basis and structure-activity relationships of the Duffy blood group antigens: chemokine and Plasmodium vivax receptors. Transfus Clin Biol 2000, 7:497-509.
• [20]Tournamille C, Filipe A, Wasniowska K, Gane P, Lisowska E, Cartron JP, Colin Y, Le Van Kim C: Structure-function analysis of the extracellular domains of the Duffy antigen/receptor for chemokines: characterization of antibody and chemokine binding sites. Br J Haematol 2003, 122:1014-1023.
• [21]Woolley IJ, Hotmire KA, Sramkoski RM, Zimmerman PA, Kazura JW: Differential expression of the duffy antigen receptor for chemokines according to RBC age and FY genotype. Transfusion 2000, 40:949-953.
• [22]Yan L, Fu Q, Jin L, Li L: Duffy blood group phenotypes and genotypes in Chinese. Transfusion 2001, 41:970.
• [23]Laura S, Coombs NJ, Ung O, Boyages J: Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J Surg 2006, 76:1002-1006.